Literature DB >> 19937483

A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A.

Tomoko Matsumoto1, Keiji Nogami2, Kenichi Ogiwara1, Midori Shima1.   

Abstract

Discrepancies between low levels of FVIII:C and clinical symptoms in severe hemophilia A are well-known. We have recently demonstrated that levels of FVIII:C < 0.2 IU/dl were consistent with clinical phenotype by clot waveform analysis, suggesting that precise measurement of very low levels of FVIII:C was clinically important. Thrombin generation tests (TGTs) triggered by tissue factor (TF) have been recently utilized to monitor coagulation function in hemophilia A. We examined whether TGT was useful for evaluating hemophilia A patients with very low levels of FVIII:C. TGTs in 40 hemophilia A plasmas with FVIII:C < 0.2-17 IU/dl (measured by clot waveform analysis using MDA-II) were performed using TF and/or ellagic acid (ELG). The lagtime in ELG-TGT at very low levels of FVIII:C was shortened dose-dependently, whilst this parameter in TF-TGT was not significantly affected. Other parameters (endogenous thrombin potential, peak thrombin, time to peak) correlated with FVIII:C levels to some extent in both assays (r = 0.4-0.7). Using a TF/ELG mixture in TGT, however, the correlation coefficients increased to ~0.85. TGT parameters correlated well with levels of FVIII:C > 0.2 IU/dl, although the lagtime was not especially informative. We conclude that modified TGT, using a TF/ELG mixture as the trigger, is useful for monitoring coagulation function at very low levels of FVIII:C in hemophilia A.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19937483     DOI: 10.1007/s12185-009-0450-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

Review 1.  A cell-based model of coagulation and the role of factor VIIa.

Authors:  Maureane Hoffman
Journal:  Blood Rev       Date:  2003-09       Impact factor: 8.250

2.  Properties of optical data from activated partial thromboplastin time and prothrombin time assays.

Authors:  P J Braun; T B Givens; A G Stead; L R Beck; S A Gooch; R J Swan; T J Fischer
Journal:  Thromb Haemost       Date:  1997-09       Impact factor: 5.249

3.  The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C).

Authors:  Midori Shima; Tomoko Matsumoto; Kazuyoshi Fukuda; Youko Kubota; Ichiro Tanaka; Katumi Nishiya; Alan R Giles; Akira Yoshioka
Journal:  Thromb Haemost       Date:  2002-03       Impact factor: 5.249

Review 4.  Thrombin generation testing in routine clinical practice: are we there yet?

Authors:  J J van Veen; A Gatt; M Makris
Journal:  Br J Haematol       Date:  2008-06-28       Impact factor: 6.998

5.  Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters.

Authors:  Joost J van Veen; Alex Gatt; Peter C Cooper; Steven Kitchen; Annette E Bowyer; Mike Makris
Journal:  Blood Coagul Fibrinolysis       Date:  2008-04       Impact factor: 1.276

6.  A modified thrombin generation test for the measurement of factor VIII concentrates.

Authors:  J H McIntosh; D Owens; C A Lee; S Raut; T W Barrowcliffe
Journal:  J Thromb Haemost       Date:  2003-05       Impact factor: 5.824

Review 7.  The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability.

Authors:  H C Hemker; P Giesen; R AlDieri; V Regnault; E de Smed; R Wagenvoord; T Lecompte; S Béguin
Journal:  Pathophysiol Haemost Thromb       Date:  2002 Sep-Dec

Review 8.  New assays for monitoring haemophilia treatment.

Authors:  M Shima; T Matsumoto; K Ogiwara
Journal:  Haemophilia       Date:  2008-07       Impact factor: 4.287

9.  Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype.

Authors:  M Trossaërt; V Regnault; M Sigaud; P Boisseau; E Fressinaud; T Lecompte
Journal:  J Thromb Haemost       Date:  2007-11-28       Impact factor: 5.824

10.  Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference.

Authors:  M Okuda; Y Yamamoto
Journal:  Clin Lab Haematol       Date:  2004-06
View more
  4 in total

1.  Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.

Authors:  Kenichi Ogiwara; Keiji Nogami; Tomoko Matsumoto; Midori Shima
Journal:  Int J Hematol       Date:  2014-04-01       Impact factor: 2.490

2.  A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.

Authors:  Tomoko Matsumoto; Keiji Nogami; Midori Shima
Journal:  Int J Hematol       Date:  2016-10-11       Impact factor: 2.490

3.  CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.

Authors:  Tsukasa Ohmori; Yasumitsu Nagao; Hiroaki Mizukami; Asuka Sakata; Shin-Ichi Muramatsu; Keiya Ozawa; Shin-Ichi Tominaga; Yutaka Hanazono; Satoshi Nishimura; Osamu Nureki; Yoichi Sakata
Journal:  Sci Rep       Date:  2017-06-23       Impact factor: 4.379

4.  Assessing the individual roles of FII, FV, and FX activity in the thrombin generation process.

Authors:  Cuicui Bai; Joke Konings; Marisa Ninivaggi; Marcus Lancé; Bas de Laat; Romy de Laat-Kremers
Journal:  Front Cardiovasc Med       Date:  2022-09-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.